Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L18a pseudogene 16 is a processed pseudogene, meaning it is a non-functional segment of DNA that arose from the ribosomal protein L18a gene (RPL18A) via retrotransposition. It retains high sequence similarity to the functional gene but does not encode a protein and is not expressed. Like other ribosomal protein pseudogenes, RPL18AP16 has no recognized biological function or implication in disease, nor is it a target for drug development[1][2][4][7].\n\nRPL18AP16 is a correctly named processed pseudogene related to ribosomal protein L18a, has no biological or therapeutic function, and is not a target for drugs or biomarker applications[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L18a pseudogene 16 (RPL18AP16).